2. Search Result
Search Result
Results for "

Deruxtecan

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

9

Fluorescent Dyes

2

Biochemical Assay Reagents

4

Inhibitory Antibodies

8

Isotope-Labeled Compounds

2

GMP Molecules

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-13631E
    Deruxtecan
    Maximum Cited Publications
    25 Publications Verification

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-141598
    Datopotamab deruxtecan (solution)
    2 Publications Verification

    DS-1062 (solution); Dato-DXd (solution)

    		 TROP2 Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .
    Datopotamab deruxtecan (solution)
  • HY-138298A
    Trastuzumab deruxtecan
    5 Publications Verification

    T-DXd; DS-8201; DS-8201a

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan
  • HY-138298
    Trastuzumab deruxtecan (solution)
    5 Publications Verification

    T-DXd (solution); DS-8201 (solution); DS-8201a (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan (solution)
  • HY-P99843
    Datopotamab
    1 Publications Verification

    		 TROP2 ADC Antibody Cancer
    Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .
    Datopotamab
  • HY-P9985
    Disitamab vedotin
    5 Publications Verification

    RC48

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .
    Disitamab vedotin
  • HY-P3371
    Ifinatamab deruxtecan

    DS-7300a; MABX-9001a; I-DXd

    		 Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis Cancer
    Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
    Ifinatamab deruxtecan
  • HY-153892
    Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide is the drug-linker conjugate for ADC, containing ADC linker Gly-Mal-GGFG and ADC cytotoxin Deruxtecan 2-hydroxypropanamide .
    Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide
  • HY-P99813
    Patritumab deruxtecan

    HER3-DXd; U3-1402

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
    Patritumab deruxtecan
  • HY-164152A
    ADC Control Human IgG1-Deruxtecan (DAR 8)

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
    ADC Control Human IgG1-Deruxtecan (DAR 8)
  • HY-164152
    ADC Control Human IgG1-Deruxtecan (DAR 4)

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
    ADC Control Human IgG1-Deruxtecan (DAR 4)
  • HY-153891
    Deruxtecan 2-hydroxypropanamide

    		Drug Intermediate Cancer
    Deruxtecan 2-hydroxypropanamide is a highly stable Deruxtecan (HY-13631E) analog that specifically binds to receptors highly expressed in tumor cells .
    Deruxtecan 2-hydroxypropanamide
  • HY-164734
    Raludotatug Deruxtecan

    R-DXd; DS-6000

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC50 of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma .
    Raludotatug Deruxtecan
  • HY-P990028
    Raludotatug

    		ADC Antibody Transmembrane Glycoprotein Cancer
    Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
    Raludotatug
  • HY-45672
    Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH

    		ADC Linker Cancer
    Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .
    Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH
  • HY-13631EG
    Deruxtecan

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-177442
    DS-3939a

    DS-3939

    		 Antibody-Drug Conjugates (ADCs) Mucin Topoisomerase Apoptosis Cancer
    DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
    DS-3939a
  • HY-164835
    VcMMAE-Deruxtecan

    SMP-54418

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Topoisomerase Cancer
    VcMMAE-Deruxtecan (SMP-54418) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Exatecan (HY-13631) (DNA topoisomerase I inhibitor). VcMMAE-Deruxtecan can be used for ADC synthesis.
    VcMMAE-Deruxtecan
  • HY-13631ES4
    Deruxtecan-d5

    MC-GGFG-DXD-d5

    		 Isotope-Labeled Compounds Drug-Linker Conjugates for ADC Cancer
    Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d5
  • HY-176415
    Cys-MC-GGFG-Dxd

    		Drug-Linker Conjugates for ADC Cancer
    Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
    Cys-MC-GGFG-Dxd
  • HY-128979
    Deruxtecan analog 2

    		Drug-Linker Conjugates for ADC Cancer
    Deruxtecan analog 2 (example 9 P3) is a Deruxtecan (HY-13631E) analog. Deruxtecan analog 2 is a agent-linker conjugate composed of Camptothecin (HY-16560) and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC .
    Deruxtecan analog 2
  • HY-13631O
    (1R)-Deruxtecan

    		Drug-Linker Conjugates for ADC Cancer
    (1R)-Deruxtecan is a drug-linker conjugates for ADC .
    (1R)-Deruxtecan
  • HY-13631ES3
    Deruxtecan-d2

    MC-GGFG-DXD-d2

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d2
  • HY-164836
    Deruxtecan-Eribulin

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Topoisomerase Cancer
    Deruxtecan-Eribulin is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Exatecan (HY-13631) (DNA topoisomerase I inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). Deruxtecan-Eribulin can be used for ADC synthesis.
    Deruxtecan-Eribulin
  • HY-13631ES
    Deruxtecan-d4

    MC-GGFG-DXD-d4

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d4
  • HY-45669
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Cbz

    		PROTAC Linkers Cancer
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Cbz is a PROTAC linker and a maleimide-GGFG peptide linker. Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Cbz can be used in the synthesis of the Deruxtecan .
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Cbz
  • HY-13631ES1
    Deruxtecan-d6

    MC-GGFG-DXD-d6

    		 Drug-Linker Conjugates for ADC Others
    Deruxtecan-d6 is the deuterium labeled Deruxtecan .
    Deruxtecan-d6
  • HY-13631ES2
    Deruxtecan-d4-1

    MC-GGFG-DXD-d4-1

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d4-1
  • HY-46346
    Fmoc-Gly-NH-CH2-O-CH2-Cbz

    		PROTAC Linkers Cancer
    Fmoc-Gly-NH-CH2-O-CH2-Cbz is a PROTAC linker and a maleimide-GGFG peptide linker. Fmoc-Gly-NH-CH2-O-CH2-Cbz can be used in the synthesis of the Deruxtecan .
    Fmoc-Gly-NH-CH2-O-CH2-Cbz
  • HY-128979B
    Deruxtecan analog 2 monoTFA

    		Drug-Linker Conjugates for ADC Cancer
    Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker .
    Deruxtecan analog 2 monoTFA
  • HY-169017
    MTT5

    		Toll-like Receptor (TLR) Cancer
    MTT5 is a toll-like receptor 7 (TLR7) agonist. MTT5 can couple with Deruxtecan (HY-13631E) and exert anti-tumor activity in HER2 positive solid tumors through tumor cell killing and immune activation .
    MTT5
  • HY-176927
    ADC-VI

    		Drug-Linker Conjugates for ADC Cancer
    ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan (HY-13631E). Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody .
    ADC-VI
  • HY-176415S
    Cys-MC-GGFG-Dxd-d5

    		Isotope-Labeled Compounds Drug-Linker Conjugates for ADC Cancer
    Cys-MC-GGFG-Dxd-d5 is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research .
    Cys-MC-GGFG-Dxd-d5
  • HY-153891S
    Deruxtecan 2-hydroxypropanamide-d5

    		Isotope-Labeled Compounds Others
    Deruxtecan 2-hydroxypropanamide-d5 is a deuterated isotope of Deruxtecan 2-hydroxypropanamide (HY-153891) .
    Deruxtecan 2-hydroxypropanamide-d5
  • HY-46398
    Fmoc-Val-Phe-Boc

    		PROTAC Linkers Cancer
    Fmoc-Val-Phe-Boc is a PROTAC linker and a maleimide-GGFG peptide linker. Fmoc-Val-Phe-Boc can be used in the synthesis of the Deruxtecan .
    Fmoc-Val-Phe-Boc
  • HY-49463
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz

    		ADC Linker Neurological Disease
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz is an ADC linker that can be used in the synthesis of ADCs (such as Trastuzumab deruxtecan and U3-1402).
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz
  • HY-49453
    Fmoc-Gly-Gly-(D-Phe)-Gly-CH2-O-CH2-Cbz

    		PROTAC Linkers Cancer
    Fmoc-Gly-Gly-(D-Phe)-Gly-CH2-O-CH2-Cbz is a PROTAC linker and a maleimide-GGFG peptide linker. Fmoc-Gly-Gly-(D-Phe)-Gly-CH2-O-CH2-Cbz can be used in the synthesis of the Deruxtecan .
    Fmoc-Gly-Gly-(D-Phe)-Gly-CH2-O-CH2-Cbz
  • HY-45672G
    Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH

    		ADC Linker Cancer
    Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-45672). Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .
    Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH
  • HY-176415S1
    Cys-MC-GGFG-Dxd-d5 TFA

    Cys-MC-GGFG-Dxd-d5 TFA

    		 Isotope-Labeled Compounds Drug-Linker Conjugates for ADC Cancer
    Cys-MC-GGFG-Dxd-d5 TFA (Cys-MC-GGFG-Dxd-d5 TFA) is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd-d5 TFA is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd-d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd-d5 TFA can be used in cancer research .
    Cys-MC-GGFG-Dxd-d5 TFA

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: